Patients with stage I NSCLC who receive stereotactic body radiotherapy rarely experience acute toxicities or 90-day mortality ...

The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...

In June, at the American Society of Clinical Oncology (ASCO) conference in Chicago, when AstraZeneca discussed results from a ...

Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...

Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.

Rybrevant (amivantamab-vmjw) has been approved by the US Food and Drug Administration (FDA) as part of a combination ...

The approval means an additional indication for osimertinib (Tagrisso; AstraZeneca) for adult patients who have unresectable ...

On September 19, the FDA handed down its third amivantamab (Rybrevant; Johnson & Johnson) approval for 2024 in non–small cell lung cancer (NSCLC), giving the third-generation tyrosine kinase inhibitor ...

Incurable lung cancer could soon become treatable, according to experts conducting a world-first trial on the NHS.

The FDA approves AstraZeneca's Tagrisso for treating unresectable, stage III EGFR-mutated non-small cell lung cancer.

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and ...

The market could potentially see the emergence of new biotech industry leaders. Since the year started, Viking Therapeutics ...